Fresenius Medical Care (ETR:FME) Shares Cross Below 200-Day Moving Average - Time to Sell?

Key Points

• Fresenius Medical Care AG shares fell below their 200-day moving average of €45.64 during trading, indicating potential bearish momentum.
• The company's current stock price is €45.72 with a market capitalization of $13.67 billion and a price-to-earnings ratio of 20.75.
• Fresenius Medical Care provides dialysis services globally, focusing on outpatient care and support for patients with renal diseases.

Fresenius Medical Care AG (ETR:FME - ) passed below its two hundred day moving average during trading on Tuesday . The stock has a two hundred day moving average of €45.64 ($53.07) and traded as low as €45.27 ($52.64). Fresenius Medical Care shares last traded at €45.72 ($53.16), with a volume of 239,109 shares trading hands.

Fresenius Medical Care Stock Performance

The stock has a market capitalization of $13.67 billion, a price-to-earnings ratio of 20.75, a PEG ratio of 0.42 and a beta of 0.86. The stock's 50 day moving average is €43.16 and its 200 day moving average is €45.64. The company has a current ratio of 1.37, a quick ratio of 0.80 and a debt-to-equity ratio of 82.24.

About Fresenius Medical Care

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.